Cross-border M&A wizardry produces Valneva from Vivalis & Intercell
This article was originally published in Scrip
Executive Summary
Technology licensing firm Vivalis of France and vaccine company Intercell of Austria have broken new ground for technical sophistication in engineering a cross-border merger agreement that combines elements of financing and preferred share conditionality. The two companies expect to complete their merger of equals next May to form a new company focused on vaccines and antibodies. It will be called Valneva, headquartered in Lyon, France, and listed on the NYSE Euronext in Paris and the Vienna Stock Exchange.
You may also be interested in...
Lyme Disease Vaccine Pushes Valneva To US Listing
Thomas Lingelbach talks to Scrip about Valneva’s plans for a US IPO to fund Phase III studies of its lead Lyme disease vaccine.
Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.
Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.